Screening Plus Corneal Cross‐Linking for Keratoconus Is Cost‐Effective for New Zealand: A Proof‐of‐Concept Markov Analysis
Screening for keratoconus at age 15 with corneal cross-linking treatment for children who screened positive is likely to be cost saving. Our results support the need for a real-world trial and cost-effectiveness analysis in New Zealand to ensure that we identify and treat those at risk early in the disease course before significant vision loss has occurred.
Authors
- Sheng Chiong Hong (ORCID: https://orcid.org/0000-0001-8954-1433)
- Chuen Yen Hong (ORCID: https://orcid.org/0000-0002-7825-9237)
- Graham Wilson (ORCID: https://orcid.org/0000-0001-6310-5721)
Institutions
- Statistics New Zealand (NZ)
- Southern District Health Board (NZ)
- Eye Care Associates (US)
Publication Details
- Journal
- Clinical and Experimental Ophthalmology
- Published
- 2025-09-08
- DOI
- https://doi.org/10.1111/ceo.14604
- Primary Topic
- Corneal surgery and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00